346 related articles for article (PubMed ID: 16161208)
1. Patent. Battle lines are drawn over generic AIDS drug.
AIDS Policy Law; 2005 Aug; 20(16):6. PubMed ID: 16161208
[No Abstract] [Full Text] [Related]
2. Patent infringement. Generic HIV drugmaker's patent claim is time-barred.
AIDS Policy Law; 2003 Aug; 18(16):6. PubMed ID: 14626916
[No Abstract] [Full Text] [Related]
3. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity.
Berger JM
Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292
[No Abstract] [Full Text] [Related]
4. . . . and Brazilian AIDS programme threatened by US trade action.
Int J Epidemiol; 2001 Apr; 30(2):413. PubMed ID: 11369751
[No Abstract] [Full Text] [Related]
5. Amendments to the Canadian Patent Act to address drug access: is help on the way?
Penner MD; Narayanan P
Food Drug Law J; 2005; 60(3):459-70. PubMed ID: 16304751
[No Abstract] [Full Text] [Related]
6. TRIPS: generic irony.
Howarth GR
Br J Gen Pract; 2002 Jan; 52(474):57. PubMed ID: 11791819
[No Abstract] [Full Text] [Related]
7. Generics battle brand names over mortality of drug patents.
Betz R
J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008
[No Abstract] [Full Text] [Related]
8. Action alert: drug-patent bill could cost patients $3 billion+; hearing July 1.
AIDS Treat News; 1999 Jun; (No 321):8. PubMed ID: 11366716
[TBL] [Abstract][Full Text] [Related]
9. AIDS drugs. Brazil, Thailand override big pharma patents.
Cohen J
Science; 2007 May; 316(5826):816. PubMed ID: 17495145
[No Abstract] [Full Text] [Related]
10. Drug patent protection: how long is long enough?
Sibbald B
CMAJ; 2001 May; 164(9):1331. PubMed ID: 11341146
[No Abstract] [Full Text] [Related]
11. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
Paine CS
Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
[No Abstract] [Full Text] [Related]
12. European Commission targets drug firms over illegal patent protection.
Watson R
BMJ; 2010 Jan; 340():c268. PubMed ID: 20080819
[No Abstract] [Full Text] [Related]
13. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
Soehnge H
Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
[No Abstract] [Full Text] [Related]
14. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
McPhie DC
Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
[No Abstract] [Full Text] [Related]
15. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
Lewis RA
J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987
[No Abstract] [Full Text] [Related]
16. Intellectual property. Balancing innovation and access: patent challenges tip the scales.
Higgins MJ; Graham SJ
Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944
[No Abstract] [Full Text] [Related]
17. Legal challenge to India's patent laws threatens access to generic drugs, says charity.
Moszynski P
BMJ; 2011 Sep; 343():d5753. PubMed ID: 21908529
[No Abstract] [Full Text] [Related]
18. [The patent legislation in India fails the HIV/AIDS work].
Holen Ø
Tidsskr Nor Laegeforen; 2005 Oct; 125(19):2666-7. PubMed ID: 16215618
[No Abstract] [Full Text] [Related]
19. Brazil and USA at loggerheads over production of generic antiretrovirals.
Ahmad K
Lancet; 2001 Feb; 357(9254):453. PubMed ID: 11273079
[No Abstract] [Full Text] [Related]
20. Health policy or intellectual property policy? The fight over Bill C-91. Canadian Healthcare Association.
Int J Health Care Qual Assur Inc Leadersh Health Serv; 1997; 10(2-3):vii-x. PubMed ID: 10169229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]